A device for a tissue channel includes a device frame, a shape memory polymer foam segment coupled to the device frame, and an attachment structure coupled to the device frame. The device frame includes a proximal structure, a distal structure, and an intermediate structure coupled to the proximal structure and the distal structure. The proximal structure is configured to collapse to fit into a delivery structure and expand to block migration of the proximal structure. The distal structure is configured to collapse to fit into the delivery structure and expand to block migration of the distal structure. The intermediate structure is configured to fit in the tissue channel upon device deployment. The shape memory polymer foam segment is configured to compress to fit into the delivery structure and occlude the channel. The attachment structure is configured to attach and detach the device from a delivery guide.

Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

A glass material that includes: from about 0.55 to about 0.85 mole fraction of SiO.sub.2; from about 0.01 to about 0.23 mole fraction of Na.sub.2O, K.sub.2O, or a combination of Na.sub.2O and K.sub.2O; from about 0.05 to about 0.28 mole fraction of: Y.sub.2O.sub.3, BaO, or a combination of Y.sub.2O.sub.3 and BaO; and optionally Ta.sub.2O.sub.5. In the glass material, the sum of the Y.sub.2O.sub.3, the BaO and the optional Ta.sub.2O.sub.5 is from about 0.10 to about 0.31 mole fraction. The glass material may be in the form of microspheres. The microspheres may be used for vascular embolization and/or radiologic imaging.

Systems and methods of blocking a biological vessel 2 are provided. The systems and methods may comprise introducing to the vessel an amphiphilic peptide. The peptide may comprise at least thirteen amino acids that may alternate between a hydrophobic amino acid and a hydrophilic amino acid. The peptide may form a beta- sheet spontaneously in an aqueous solution in the presence of a cation.

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.

Provided herein are methods, compositions, and devices for occluding cavities or passageways in a patient, in particular cavities or passageways in the cardiovascular system of a patient, such as the LAA of a patient's heart. The methods, compositions, and devices can be used to percutaneously occlude the LAA, decreasing the risk of thromboembolic events associated with AF.

Microcatheters and methods for modifying and delivering suspended particles to target bodily parts (e.g., of a cardiovascular system). Embolization microcatheters and uses thereof in performing local embolization procedures, involving modifying flow characteristics (momentum) of suspensions during delivery. Applicable for delivering embolization material in a small blood vessel towards a target bodily part, and for performing local embolizations in small blood vessels feeding (possibly, cancerous) target bodily parts, thereby forming emboli therein, while preventing or minimizing non-target embolization. An exemplary catheter includes: a tubular wall with proximal and distal wall ends, and a lumen extending therebetween, opened and configured to allow passage of a suspension to a distal outlet; the distal outlet shaped or/and sized to allow passage of both a suspension fluid and particles; a proximal outlet configured to allow passage of the suspension fluid without particles and to block passage of the particles, during delivery of the suspension.

Materials and methods for forming a bronchial obstruction are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to provide a bronchial obstruction.

A preparation method for a non-spherical hydrogel microparticle embolic agent is provided. The method includes: alternately injecting a oil phase solution and an aqeuous phase solution into an elongated channel, the aqueous phase solution contains a water-soluble polymer to be cross-linked, the aqueous phase solution has a cross-linking reaction in the elongated channel to obtain a product, which is then discharged from the elongated channel to obtain the non-spherical hydrogel microparticle embolic agent. This preparation method is simple in process, and the non-spherical hydrogel microparticle embolic agent obtained from this method has good embolization performance.

The invention relates to non-biodegradable embolisation microspheres comprising a cross-linked matrix, the matrix being based on at least: a) from 20% to 95% of hydrophilic monomer; b) from 1% to 15% of a non-biodegradable hydrophilic cross-linking monomer; and c) from 1.5% to less than 6% of transfer agent selected from alkyl halides and cycloaliphatic or aliphatic thiols having in particular from 2 to 24 carbon atoms, and optionally having another functional group selected from amino, hydroxy and carboxy groups. The invention further relates to a pharmaceutical composition comprising non-biodegradable embolisation microspheres according to the invention in conjunction with a pharmaceutically acceptable vehicle, advantageously for parenteral administration. The invention further relates to a kit comprising a pharmaceutical composition comprising non-biodegradable embolisation microspheres according to the invention in conjunction with a pharmaceutically acceptable vehicle for parenteral administration, and at least one injection means.